

Ref no: 027170518
From: Commercial
Date: 17/05/18
Subject: Biologics and Biosimilar prescribing

REQUEST

I have a Freedom of Information request regarding Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.

Number of patients treated	Rheumatology	Dermatology	Gastroenterology
TOTAL			
Abatacept [Orencia]			
Adalimumab [Biosimilar]			
Adalimumab [Humira]			
Apremilast [Otezla]			
Baricitinib [Olumiant]			
Brodalumab [Kyntheum]			
Certolizumab [Cimzia]			
Dimethyl fumarate [Skilarence]			
Etanercept [Enbrel]			
Etanercept Biosimilar [Benepali or Erelzi]			
Golimumab			

[Simponi]			
Guselkumab [Tremfya]			
Infliximab [Remicade]			
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]			
Ixekizumab [Taltz]			
Rituximab [Mabthera]			
Rituximab Biosimilar [Rixathon or Truxima]			
Sarilumab [Kevzara]			
Secukinumab [Cosentyx]			
Tocilizumab [Ro Actemra]			
Tofacitinib [Xeljanz]			
Ustekinumab [Stelara]			
Vedolizumab [Entyvio]			

RESPONSE

Pharmacy System Data 1st April 2017 to 31st March 2018

Distinct Count of Patients issued with selected drug to speciality.

N.B A number of patients may have been issued with one or more strengths of the drug.

Number of patients treated	Dermatology	Gastroenterology	Rheumatology
TOTAL	117	340	655
Abatacept [Orencia]	0	0	27
Adalimumab [Biosimilar]	0	0	0

Adalimumab [Humira]	50	81	151
Apremilast [Otezla]	18	0	3
Baricitinib [Olumiant]	0	0	7
Brodalumab [Kyntheum]	0	0	0
Certolizumab [Cimzia]	0	0	18
Dimethyl fumarate [Skilarence]	25	0	0
Etanercept [Enbrel]	2	0	92
Etanercept Biosimilar [Benepali or Erelzi]	0	0	109
Golimumab [Simponi]	0	9	43
Guselkumab [Tremfya]	0	0	0
Infliximab [Remicade]	0	1	8
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	0	208	11
Ixekizumab [Taltz]	0	0	0
Rituximab [Mabthera]	0	0	62
Rituximab Biosimilar [Rixathon or Truxima]	0	0	28
Sarilumab [Kevzara]	0	0	0
Secukinumab [Cosentyx]	2	0	10
Tocilizumab [Ro Actemra]	2	0	74
Tofacitinib [Xeljanz]	0	0	0
Ustekinumab [Stelara]	17	17	12
Vedolizumab	1	24	0

[Entyvio]			
-----------	--	--	--